Navigation Links
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
Date:5/30/2009

Promising Anti-cancer Activity Observed in Relapsed Patients

ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc. today reported on clinical advances for its carfilzomib solid tumor program in an oral presentation at the 2009 Annual Meeting of the American Society of Oncology (ASCO) in Orlando, Florida. Data from a Phase 1b study and an ongoing Phase 2 clinical trial of carfilzomib in relapsed patients with advanced solid tumors demonstrate promising single-agent anti-cancer activity. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors.

"In these clinical studies, carfilzomib demonstrated promising activity as a highly selective and potent inhibitor of the proteasome for treatment of solid tumor patients. The compound's unique characteristics enable the drug to be well tolerated with consecutive day dosing, which in turn appears to improve anti-cancer activity. Early results among patients with late-stage or metastatic solid tumors who have failed multiple prior treatments are encouraging, with a number of patients achieving stable disease or better lasting for several months," said Peter J. Rosen, M.D., Medical Director of the Tower Cancer Research Foundation and Emeritus Professor, UCLA.

Data from the Phase 1b/2 clinical trials of relapsed solid tumor patients were presented by Dr. Rosen at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in an oral presentation titled "Phase II results of Study PX-171-007: A Phase Ib/II study of carfilzomib (CFZ), a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors" (Abstract #3515).

The Phase 1b dose-escalating clinical trial enrolled patients with a variety of relapsed solid tumors established a dosing schedul
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
2. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
7. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
10. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
11. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BOCA RATON, Fla. , Dec. 19, 2014 /PRNewswire/ ... entered into a multi-product agreement with MSN Laboratories Pvt. ... Breckenridge and MSN expect to commercialize several new ANDAs. ... manufacture, and supply the products exclusively to Breckenridge for ... the products under its label.  Breckenridge and MSN have ...
(Date:12/19/2014)... HILL, N.C. , Dec. 19, 2014 /PRNewswire/ ... to optimize a product,s web presence to reflect ... Brand websites, in particular, must meet the needs ... regulations and culture. According to ... more than half of the participating companies averaged ...
(Date:12/19/2014)... 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch America" ... to provide this review of the Company,s recent achievements ... "Over this past year, we achieved many of ... proud to say that Monarch America is in a ... ever been," stated Eric Hagen , CEO of ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
... 14, 2011  Heska Corporation (NASDAQ: HSKA ; ... and specialty products to veterinarians, announced today the intent ... expertise in blood-related disorders.  The parties are to explore ... cell-based therapeutics, for use in the veterinary market.      ...
... Group, Inc. (OTCMARKETS: UYMG) "UNITY" (or the "Company"), and its ... it has sold its initial PZ Uno Tablet press to ... the company is not able to disclose the name of ... tablet press would be used for a research and development ...
Cached Medicine Technology:Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc. 2Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc. 3Unity Management Group, Inc. Announces Its Initial Sale of the PZ UNO Tablet Press to a Major Pharmaceutical Company for $500,000 2
(Date:12/20/2014)... December 20, 2014 Weddingshe.com has recently ... launched a site-wide promotion of special occasion dresses for ... popular supplier of special occasion dresses for global women. ... with big discounts, up to 80% off. Among the ... Sequins Short Sweet 16 Dress) is very popular. What’s ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
(Date:12/20/2014)... 20, 2014 Recently, VogueQueen.com, a leading ... VogueQueen Big Sale Online for 2015. Great discounts ... new and old consumers can get a discount, up ... the company’s website before January 30, 2015. , VogueQueen.com ... and launched a prom dress promotion. Many customers worldwide ...
(Date:12/20/2014)... York (PRWEB) December 20, 2014 ... to move forward in U.S. courts, Bernstein Liebhard ... which suggests that children treated with the medication ... linked to breast development and lactation. The study, ... 34 children and adolescents who began treatment with ...
(Date:12/20/2014)... Recently, AngelWeddingDress.com has introduced its special offer ... coming Christmas. In the promotion, all buyers worldwide can ... have something special for the women who are looking ... our new collections of 2015 dresses have been unveiled ... greatly discounted prices. Visit our website now before they ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... March 31 /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX: RBM, ... $4,084,116 and a net loss of $13,901,041 or ... 2007. Additionally, the Company announced,that as of December ... working,capital. For a further discussion of the Company,s ...
... /Xinhua-PRNewswire/ -- China Medicine,Corporation (OTC Bulletin Board: ... distributor and developer of prescription and over-the-counter,pharmaceuticals, ... medical devices, and medical formulations in the ... at the upcoming Brean Murray,Carret & Co. ...
... to Benefit Prevention, Control Efforts in Every,County, HARRISBURG, ... from an aggressive effort to monitor and control,mosquitoes this ... a $5.3 million investment that will help fight to ... the past several years to protect the,public,s health by ...
... March 31 CNS Response,Inc. (OTC Bulletin ... its,agreement to roll out referenced-EEG(R) (rEEG(R)) availability ... (MBHO). This,agreement enables psychiatrists under the management ... medication guidance to treat their most,therapy-challenged patients ...
... LAKES, NJ, STOCKHOLM, Sweden, March 31 /PRNewswire-FirstCall/,-- ... ) today announced a collaboration,with Sweden,s government-operated ... the first automated electronic prescription-review system,to improve ... and the,country,s health care system., Under ...
... congratulated,Third Wave Technologies Inc., Madison, Wis., on the ... CLIA-certified SeqWright is,a leader in the field of ... validated the InPlex(TM) CF test by,demonstrating it had ... a critical role in the test gaining FDA ...
Cached Medicine News:Health News:Response Biomedical Corporation Reports 2007 Financial Results 2Health News:Response Biomedical Corporation Reports 2007 Financial Results 3Health News:Response Biomedical Corporation Reports 2007 Financial Results 4Health News:Response Biomedical Corporation Reports 2007 Financial Results 5Health News:China Medicine Corporation to Present at Brean Murray Carret & Co. Mainland China Investor Tour 2Health News:Governor Rendell Proposes County Grants to Combat West Nile Virus, Protect Public Health 2Health News:Governor Rendell Proposes County Grants to Combat West Nile Virus, Protect Public Health 3Health News:Governor Rendell Proposes County Grants to Combat West Nile Virus, Protect Public Health 4Health News:Governor Rendell Proposes County Grants to Combat West Nile Virus, Protect Public Health 5Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 2Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 3Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 4Health News:Medco Partners to Develop Patient-Safety System for Prescription Drugs in Sweden 2Health News:Medco Partners to Develop Patient-Safety System for Prescription Drugs in Sweden 3Health News:SeqWright's Partnership With Third Wave Contributes to FDA Success 2
... a cruciate sparing version which provides ... both resurfacing and inset patellas. Precision ... and fit with tibial articular surface ... cutting guide peg locations provide easy ...
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results....
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
... The Duracon tibial inserts have radiused ... advanced 4-axis machining, maximizing conformity of ... condyles of the femoral component. The ... the Duracon system, and accommodates the ...
Medicine Products: